MEGALENCEPHALY-CAPILLARY MALFORMATION POLYMICROGYRIA SYNDROME (MCAP)
Clinical trials for MEGALENCEPHALY-CAPILLARY MALFORMATION POLYMICROGYRIA SYNDROME (MCAP) explained in plain language.
Never miss a new study
Get alerted when new MEGALENCEPHALY-CAPILLARY MALFORMATION POLYMICROGYRIA SYNDROME (MCAP) trials appear
Sign up with your email to follow new studies for MEGALENCEPHALY-CAPILLARY MALFORMATION POLYMICROGYRIA SYNDROME (MCAP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare brain disorder: drug trial targets MCAP symptoms
Disease control Recruiting nowThis study tests a drug called alpelisib in 20 people aged 2 to 40 with MCAP syndrome, a rare condition causing an enlarged brain and developmental delays. The goal is to see if the drug improves daily living skills, communication, and social abilities over 6 months compared to a…
Matched conditions: MEGALENCEPHALY-CAPILLARY MALFORMATION POLYMICROGYRIA SYNDROME (MCAP)
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated May 26, 2026 04:26 UTC
-
New drug aims to shrink overgrown tissue in rare genetic disorder
Disease control Recruiting nowThis study tests a new drug, RLY-2608, in adults and children with rare conditions that cause abnormal overgrowth of body parts (like limbs or organs) due to a PIK3CA gene mutation. The drug targets only the mutated protein to try to reduce the size of overgrown tissue and improv…
Matched conditions: MEGALENCEPHALY-CAPILLARY MALFORMATION POLYMICROGYRIA SYNDROME (MCAP)
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 04:14 UTC